Neprinol is an enzyme based natural blood thinner which far surpasses other blood thinners available on the market. It has undergone extensive clinical research which has more than proven its safety and ability to deliver results. Men and women who have used Neprinol have reported results similar to its pharmaceutical counterparts, but without the typical side effects associated with blood thinners. In patients taking Neprinol fibrinogen, Factor VII and Factor VIII (coagulation factors) were all found to decrease with no notable adverse events.
Pradaxa, is the latest pharmaceutical blood thinner in the market. It is being studied for various clinical indications and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant ("blood thinner") since it does not require frequent blood tests This blood thinner has undergone years of intensive research and clinical tests. The U.S. Food and Drug Administration (FDA) approved Pradaxa on October 19, 2010, for prevention of stroke in patients with non-valvular atrial fibrillation.
Aspirin is perhaps the most well-known and commonly used blood thinner. Low doses of aspirin are recommended for the secondary prevention of strokes and heart attacks. For both males and females diagnosed with cardiovascular disease, aspirin reduces the chance of a heart attack and ischaemic stroke by about a fifth. This translates to an absolute rate reduction from 8.2% to 6.7% of such events per year for people already with cardiovascular disease. According to an estimate around 40,000 tons of aspirin are used every year. The history of aspirin can be traced back centuries when it was derived from willow bark. However, the aspirin in the form we know today was created in the nineteenth century.
Argatroban is a relatively new blood thinner in the market. The drug is made by Glaxo Smith Kline and sold by Encysive Pharmaceuticals. It is a small molecule direct thrombin inhibitor derived from L-arginine. In many cases it is considered to be a safer replacement for heparin. In the year 2000 the Food and Drug Administration (FDA) granted license to argatroban as a treatment for thrombosis in patients with heparin-induced thrombocytopenia (HIT). This blood thinner metabolized in the liver and has a life span of about 50 minutes.
Another blood thinner which is widely used especially in hospitals is Clexane. Clexane is the brand name of the chemical Enoxaparin and belongs to the Heparin family. It is one of the oldest drugs which are still used. Clexane is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. Enoxaparin is manufactured by Sanofi-Aventis. Clexane is derived from liver, lung, mast cells, etc., of vertebrates including the intestinal mucosa of pigs. These compounds are usually taken directly from the blood of animals and then processed in labs to isolate only certain members of the Heparin family.
Coumadin is one of the most widely used blood thinners on the market. Manufactured by Bristol-Myers Squibb, it has been used since the 1950s and has maintained a steady popularity despite certain adverse side effects. Coumadin is the brand name for the chemical Warfarin which was initially used as a pesticide against the menace of rats and other vermin. Its properties as an effective blood thinner were later discovered and it has ranked as one of the most used blood thinners in the US. Warfarin is a synthetic derivative of dicoumarol, a 4-hydroxycoumarin-derived mycotoxin anticoagulant. It was originally derived from sweet clover based animal feed. Coumadin should never be taken without a doctor’s prescription.
Dietary supplementation with Nattokinase was shown to suppress Intimal Thickening (thickening of the blood vessel wall) following induced injury of the rat femoral artery and appeared to enhance tissue type plasminogen activator (t-PA) while not tending to increase bleeding versus the control group. Thus, orally administered nattokinase could be considered as a cardiovascular disease (CVD) nutraceutical by decreasing plasma levels of these blood clotting factors associated with an increased CVD risk. Fibrinolytic activity, the amounts of t-PA, and fibrin degradation by-product in the plasma are doubled when nattokinase is given to human subjects by oral administration.
Nattokinase has clot-dissolving capabilities like that of our own fibrin-degrading enzyme plasmin. Plasmin is a natural human enzyme found in the blood and serves as a defense system to get rid of superfluous blood clots. Nattokinase increases the human body's ability to battle blood clots through multiple methods, because of its ability to up-regulate plasmin levels. In tests with 45 human subjects taking 2 capsules/day nattokinase orally, systemic levels of fibrinogen, Factor VII and Factor VIII (coagulation factors) were all found to decrease with no notable adverse events.
Anti-coagulants, or blood thinners, are used to stop platelets in the blood's plasma from forming clots. People who are at risk of a heart attack, stroke or an aneurysm are most often prescribed blood thinning medications. Some blood thinners are comprised of many different chemicals, while others like aspirin are one drug. Although they are called blood thinners, blood thinning medications do not actually thin the blood. Instead, they decrease the blood's ability to clot.
Blood coagulation or blood clotting is the transformation of blood into a solid gel called a clot or thrombus. The clot consists of a lattice of a protein polymer known as fibrin in combination with activated platelets. Clotting occurs in response to injury in the blood vessel.